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Abstract
Purpose. To study the long-term neurotoxicity of chemotherapy in adolescents and young adults treated for bone and soft
tissue sarcomas.
Patients and Methods. Thirty-six adolescents and young adults (median age 17 years) were examined following chemo-
therapy for bone and soft tissue sarcomas. Twenty-nine (29/36) had received cisplatin (median 400 mg/m
2), 15/36
ifosfamide (median 20 g/m
2), and 12/36 vincristine (median 16 mg). Neurotoxicity was assessed at a median of 8 months
(range, 1± 54 months) after completion of chemotherapy by clinical examination, nerve conduction studies, audiograms
and autonomic function tests. The same nerve conduction studies were carried out in 20 normal volunteers to de® ne
normal ranges in this age group.
Results. Sixteen patients (44%) had a signi® cant reduction in deep tendon re¯ exes, and this clinical parameter correlated
well with abnormalities detected in nerve conduction studies. Vibration perception threshold (VPT) was raised in 20/36
patients (55%) and this was the most sensitive single test in the assessment of neuropathy. There was a signi® cant
correlation between VPT and cumulative cisplatin dose received in mg/m
2 (r5 0.607, p , 0.01). Ten of 29 patients (35%)
had abnormal nerve conduction studies with a pattern characteristic of sensory axonal neuropathy. No patient complained
of auditory symptoms, but minor high tone hearing loss was detected by audiograms in 5/28 patients who had received
cisplatin. No patients had symptoms of autonomic neuropathy, but autonomic function tests showed minor abnormalities
in 4/22 patients tested, and all had received cisplatin.
Conclusions. This study demonstrates signi® cant, although asymptomatic, long-term neurotoxicity of cisplatin in adoles-
cents and young adults receiving chemotherapy for bone and soft tissue sarcomas. Follow-up studies are planned to assess
whether these neurological de® cits improve with time.
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Introduction
Intensive combination chemotherapy has greatly im-
proved the prognosis of childhood and adolescent
tumours. In osteosarcomas, for example, the cure
rates for UK children under the age of 16 years have
risen from 20% in the mid-1970s, to 60% at the
present time, an improvement attributable to inten-
sive adjuvant chemotherapy.
1 Similar advances are
now taking place in the treatment of Ewing’s sar-
coma.
2 This is a considerable triumph for modern
cancer management. The long-term adverse effects
of cancer treatments in adolescents are of consider-
able importance since, each year in the UK, 1200
young adults will have a history of having been
cured of a cancer in childhood or adolescence. If
their life span is normal this will represent over
50 000 UK adults by the year 2030.
There is little published data on long-term neuro-
toxicity of chemotherapy in the adolescent age
group. Indeed, the normal ranges in adolescents are
not well established for many of the available tests of
neurological function. Previous studies have not al-
ways stated what the reference population has
been.
3,4 Although the reported neurotoxicity has
not, in the main, been clinically severe, it is import-
ant nonetheless to establish the frequency and
severity of sub-clinical neurotoxicity. Chemo-
therapy-induced nerve damage may have important
implications for the future, because other potentially
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neurotoxic compounds may have an additive neuro-
toxic effect in these patients. In later life, common
illnesses such as diabetes may produce more severe
neuropathy because the starting point is not one of
a normal peripheral nervous system.
The aim of the present study was to establish the
frequency and severity of long-term sub-clinical
neurotoxicity from cytotoxics currently used in ado-
lescents and young adults with bone and soft tissue
sarcomas, compared with a reference population of
normal volunteers of similar age, using the same
methodology.
Patients and chemotherapy protocols
Thirty-six patients with bone and soft tissue sarco-
mas were studied. Patients’ characteristics are
shown in Table 1. There were 19 males and 17
females, with a median age at diagnosis of 17 years
(range, 3± 29 years), and a median age at assessment
of 19 years (range, 8± 30 years). Patients were as-
sessed at a median of 8 months from the completion
of chemotherapy (range, 1± 54 months). Twenty-
one patients were between 1 and 12 months, eight
patients between 13 and 24 months, and ® ve pa-
tients between 25 and 54 months from the com-
pletion of chemotherapy. Diagnoses were as follows:
osteosarcoma (28), Ewing’s sarcoma of bone (® ve),
soft tissue sarcoma (two), and spindle cell sarcoma
of bone (one). All patients were treated on National
and International protocols which included: (1)
MRC osteosarcoma protocol BO03, a randomised
study of cisplatin/doxorubicin versus multidrug ad-
juvant chemotherapy;
5,6 (2) MRC/EOI (European
Osteosarcoma Intergroup) protocol for metastatic or
axial skeleton osteosarcoma; (3) UKCCSG (United
Kingdom Children’s Cancer Study Group) protocol
for Ewing’s sarcoma of bone; (4) MRC pilot study
in osteosarcoma of cisplatin, doxorubicin, ifos-
famide and high-dose methotrexate; (5) phase 2
study of methotrexate, ifosfamide and doxorubicin
in malignant ® brous histiocytoma of bone.
7 The
protocols, chemotherapy and duration of treatment
are shown in Table 2, and the actual doses of
chemotherapy received are shown in Table 3.
Methods
Clinical examination
All patients had full clinical neurological assessment
and nerve conduction studies. Twenty-eight patients
had bilateral audiograms, and 22 patients had as-
sessment of autonomic function. Clinical neurologi-
cal history included detailed questions concerning
peripheral sensory and motor neuropathy, unsteadi-
ness, Lhermitte’s syndrome, Raynaud’s phenom-
ena.
8,9 auditory symptoms and symptoms of
autonomic neuropathy. Symptoms were assessed as
either acute (i.e., immediate, during each chemo-
therapy course), intermediate (i.e., during the 6± 12
months of chemotherapy), or as late effects (after
completion of all chemotherapy). Clinical neuro-
logical examination was carried out by the same
investigator (HME) with full neurological assess-
ment of motor and sensory systems, including joint
position sense and vibration sense (tuning fork
128 c/s). Deep tendon re¯ exes (DTRs) were as-
sessed and scored as normal (score5 1), reduced
(only present with reinforcement, score 5 0.5) or
absent (score5 0). Biceps, triceps, supinator, knee
and ankle DTRs were scored to give a maximum
cumulative normal score of 10. Re¯ ex scores of 6 or
less were considered abnormal.
Nerve conduction studies (NCS)
Neurophysiological assessment of all patients was
carried out by the same doctor (SC), who also
examined 20 healthy volunteers (14 females and six
males) ranging in age from 18 to 26 years (mean
age 5 22 years). Full neurophysiological investiga-
tions included nerve conduction studies and the
measurement of vibration perception and thermal
thresholds. Lower limb nerve conduction studies
were performed using surface electrodes and
recorded on a Medelec MS 92 electromyograph.
Recordings were made of sural and medial plantar
sensory nerve action potential (SNAP) latency and
amplitude, and sensory conduction velocities (SCV)
were calculated for these nerves. The compound
muscle action potential (CMAP) amplitude and la-
tency from ¯ exor hallucis brevis after supra-maximal
stimulation of the posterior tibial nerve at the ankle
and the knee was recorded, and the motor conduc-
tion velocity (MCV) for the nerve calculated. Re-
cord was also made of a minimum of 10 f-wave
latencies from ¯ exor hallucis brevis while giving
supra-maximal stimuli to the posterior tibial nerve at
the ankle.
The vibration perception threshold (VPT) was
measured using a Biothesiometer. This instrument
has a dial which reads the voltage applied to the
probe causing it to vibrate. The movement of the
probe (in m M) is linearly related to the square of the
voltage. With the subject in a semi-recumbent pos-
ition, the instrument was placed vertically on the
Table 1. Patient characteristics
Diagnosis Number of patients
Osteosarcoma 28
Ewing’s sarcoma 5
Soft tissue sarcoma 2
Spindle cell sarcoma of bone 1
Other characteristics (median (range)) : age at diagnosis
(years) 17 (3± 29); age at assessment (years) 19 (8± 30);
time from the end of chemotherapy (months) 8 (1± 54).Long-term neurotoxicity of chemotherapy in adolescents 99
Table 2. Adjuvant chemotherapy protocols
Intended
No. of duration
patients Diagnosis Protocol Drugs (weeks)
22 Osteosarcoma MRC BO03 Cisplatin 22
Short arm Doxorubicin
vs.
Long arm Cisplatin 44
Doxorubicin
Methotrexate
Vincristine
Bleomycin
Cyclophosphamide
Actinomycin
5 Osteosarcoma MRC/EOI/PIA Cisplatin 22
BO04 Ifosfamide
Doxorubicin
5 Ewing’s UKCCSG Ifosfamide 52
Sarcoma IVAD Doxorubicin
Actinomycin
Vincristine
2 Soft tissue Off study IVA Ifosfamide 18
sarcoma Doxorubicin
Vincristine
1 MFH of bone Phase II Study Ifosfamide 16
Doxorubicin
Methotrexate
1 Osteosarcoma MRC Pilot Ifosfamide 22
Cisplatin
Doxorubicin
MFH, malignant ® brous histiocytoma; UKCCSG, United Kingdom Childhood
Cancer Study Group; EOI, European Osteosarcoma Intergroup Study.
Table 3. Total doses of chemotherapy received
Total dose (mg/m
2)
No. of patients Drug Range Median
29 Cisplatin 170± 607 400
15 Ifosfamide 10 200± 96 000 20 000
12 Vincristine 4.7± 16 9.4
10 Methotrexate 13 000± 65 000 60 000
9 Cisplatin 170± 583 230
1 1 1
ifosfamide 10 200± 60 000 11 200
6 Cisplatin 338± 582 400
1 1 1
vincristine 4.7± 15 14
end of the great toe so that the weight of the probe
(300 gm) was supported by the toe. The stimulus
was increased from zero until the subject indicated
having felt it, and the lowest of three readings was
taken.
10 Cutaneous thresholds for warming and
cooling were recorded from the plantar surface of
the foot using a standard portable system as de-
scribed by Fowler et al.
11 Criteria for overall abnor-
mal nerve conduction studies suggestive of a sensory
axonal neuropathy were de® ned as follows: (1) ab-
sent sural SNAP (sensory nerve action potential); or
(2) abnormal VPT with either one of the following:
(a) present but abnormal sural SNAP; or (b) absent
medial plantar SNAP.
Autonomic function tests
Sympathetic function was measured by postural
changes in blood pressure. The subject lay supine
for 20 min before the BP was recorded at 1 min
intervals 3 3. On standing, BP was recorded every
minute for 5 min and then at 10 min. In normal
subjects the systolic blood pressure does not
fall . 15 mmHg.100 H. M. Earl et al.
Parasympathetic function was assessed by heart
rate response to deep breathing and the Valsalva
manouevre. The heart rate response to deep breath-
ing was assessed using a continuous ECG during six
full respiratory cycles over 1 min. The Valsalva ma-
neouvre was used to evaluate parasympathetic func-
tion by asking the patient to maintain a forced
expiratory pressure of 40 mmHg against an anaeroid
pressure monitor dial.
12 The heart rate ratio was
assessed and recorded three times; a normal ratio is
. 1.2. The results were analysed using the values
recommended by Ewing and Clarke.
12
Audiometry
Hearing was assessed by bilateral audiograms and
thresholds (dB) for detection were recorded be-
tween 250± 12 000 Hz.
Statistical analysis
The data were analysed using the Statview statistical
package on an Apple Macintosh computer. Two
groups were compared using Student’s t-test (con-
tinuous variables) and the chi-squared test (discrete
variables). Signi® cant correlations with age were
found for the SNAP amplitudes and the VPTs.
Signi® cant correlation for height was found for the
f-wave latency. Therefore, t-tests involving these
variables were calculated after correction for age or
height where relevant. All correlations were deter-
mined by calculating Kendall’s rank correlation
coef® cient (tau).
Results
Clinical parameters and audiograms
The only clinical neurological abnormality reported
was Lhermitte’s sign, which was reported by one
patient and occurred during chemotherapy. There
were no reports of symptomatic peripheral sensory
or motor neuropathy, symptoms due to autonomic
dysfunction, Raynaud’s phenomenon, tinnitus or
high tone hearing loss, as acute, intermediate or
delayed effects. Clinical neurological assessment re-
vealed no abnormalities of power (MRC scales),
tone, or coordination, and no abnormalities of the
clinically assessed sensory parameters, including
joint position sense and vibration sense. However,
the strikingly abnormal clinical parameter was the
cumulative re¯ ex score which was reduced to # 6 in
16/36 (44%) of patients. Bilateral audiograms were
abnormal in 5/28 patients with minimal loss of high
tone hearing. All ® ve patients had received cisplatin
(348± 607 mg/m
2; median, 473 mg/m
2).
Autonomic function tests
Autonomic function tests were mildly abnormal in
4/22 patients tested. Two patients had minimal
sympathetic abnormalities with systolic BP falling by
20 mmHg on standing. There was evidence of mild
parasympathetic abnormality in two patients with an
abnormal Valsalva ratio (1.2), and abnormal re-
sponse to deep breathing (heart rate increase , 15
beats/min) in one patient. All four patients with
mild autonomic dysfunction had received cisplatin
(200± 582 mg/m
2); three of these patients also had
abnormal VPTs, and two had abnormal nerve con-
duction studies (NCS) suggestive of a sensory ax-
onal neuropathy.
Neurophysiology
Normal limits for the neurophysiological parameters
were determined in healthy volunteers and ex-
pressed as mean 6 2SD, except in the cases of me-
dial plantar and sural SNAPs and VPT where the
means and SDs of the log-transformed data were
calculated and then converted back to original units
to be used as limits of normal.
13,14 Results of all the
neurophysiological data are shown in Table 4.
Comparison of control group (n 5 20) with patients who
received cisplatin alone (n 5 15). These two groups
were compared in the ® rst instance because the
patient group received only one neurotoxic drug
(cisplatin) rather than several. The two groups were
matched in age and height. The 15 patients differed
signi® cantly from the controls in the conduction
study parameters for the two sensory nerves studied
(medial plantar and sural), particularly the readings
of the sensory nerve action potential amplitudes
(p , 0.0001), but also the sensory conduction veloc-
ities (p , 0.005). There were also signi® cant differ-
ences between the patient and control groups for
vibration perception thresholds (VPTs) (p , 0.001),
and f-wave latency (p, 0.005). No signi® cant dif-
ferences were observed for other motor parameters
or thermal thresholds for warming and cooling.
An analysis of the correlation between cisplatin
dose received (mg/m
2) and the neurophysiological
parameters was made for these 15 patients. Vi-
bration perception thresholds were signi® cantly cor-
related with cisplatin dose received, but none of the
other parameters measured.
Analysis of all 29 patients who received cisplatin. All
neurophysiology parameters measured were
analysed for possible correlation with the continu-
ous variable of received cumulative dose of cisplatin
(mg/m
2). The only neurophysiological parameter
that was signi® cantly correlated with dose of cis-
platin in these patients was VPT (Fig. 1, r 5 0.607,
p , 0.001). The cumulative cisplatin dose (above or
below 300 mg/m
2) also correlated with a normal or
abnormal VPT (Fisher’s exact test, p 5 0.005) in
this group of patients. Ten out of 29 (35%) patients
had abnormal nerve conduction studies, showing a
sensory axonal neuropathy. The presence of thisLong-term neurotoxicity of chemotherapy in adolescents 101
Table 4. Nerve conduction studies: controls compared with patients receiving cisplatin alone
Controls Patients
(n 5 20) (n 5 15) Cor/plat
Mean 6 SD Normal limits Mean 6 SD p (2-tail) p value
Age (years) 22.0 6 2.5 20.8 6 4.7 0.32
Height (cm) 168 6 8.9 168 6 6.8 0.89
Sensory tests
mp SNAP* 7.6 6 3.7 2.4 m V 2.3 6 2.0 , 0.0005 0.28
mp DSL 2.7 6 0.44 3.6 ms 3.4 6 0.94 , 0.01 1.0
mp SCV 45 6 5.1 35 m s
2 1 37 6 7.5 , 0.001 0.48
surSNAP* 16.6 6 5.9 6.0 m V 8.1 6 4.5 , 0.0005 0.37
sur DSL 3.1 6 0.61 4.3 ms 3.7 6 0.68 , 0.01 0.50
sur SCV 46 6 4.9 36 m s
2 1 40 6 4.2 , 0.0005 0.22
Motor tests
CMAP 18.5 6 6.6 5.3 mV 15.0 6 5.1 0.06 0.74
DML 3.7 6 0.82 5.4 m s
2 1 3.9 6 0.58 0.51 0.11
MCV 47 6 3.1 41 m s
2 1 44 6 4.8 0.07 0.47
f-wave** 47.0 6 4.0 50.0 6 3.7 , 0.005 0.87
Vibration tests
RVPT* 5.3 6 1.5 9 units 12.1 6 7.8 , 0.005 , 0.005
LVPT* 5.3 6 1.2 8 units 11.8 6 7.6 , 0.005 , 0.05
VPTsum* 10.6 6 2.5 17 units 24.5 6 15 , 0.001 , 0.05
Thermal tests
Cool TT 0.31 6 0.3 0.9°C 0.48 6 0.3 0.07 0.77
Warm TT 0.69 6 0.6 1.9°C 0.69 6 0.6 0.99 0.10
SNAP, sensory nerve action potential; DSL, distal sensory latency; SCV, sensory conduction
velocity; CMAP, compound muscle action potential; DML, distal motor latency; MCV, motor
conduction velocity; VPT, vibration perception threshold; VPT sum, Sum of R and L VPT; TT,
thermal threshold; mp, medial plantar nerve; sur, sural nerve; Cor/plat, correlation with cisplatin
dose (mg m
2 2), *After log transformation, **after correction for height.
neuropathy correlated with the cumulative total
dose of cisplatin (mg/m
2) and re¯ ex score, but
showed no correlation with the treatment-free inter-
val, or the dose of vincristine received (Table 5).
None of the seven patients who received less than
300 mg/m
2 of cisplatin had neurophysiological evi-
dence of sensory axonal neuropathy. There was also
a signi® cant correlation between re¯ ex score and
total received cisplatin dose (r 5 2 0.483,
p 5 0.009).
Correlation of re¯ ex score with NCS abnormalities
The only consistently abnormal clinical parameter
in this group of adolescents and young adults was
the re¯ ex score. However this did prove useful as a
simple clinical marker of an otherwise sub-clinical
neuropathy. There was a signi® cant correlation be-
tween re¯ ex score and VPT (Fig. 2, r 5 2 0.548,
p , 0.001), medial plantar and sural SNAP, and
medial plantar SCV (Table 6). Re¯ ex score (normal
or abnormal) correlated with both abnormal NCS
(p , 0.005, Table 5) and abnormal VPT
(p , 0.005).
Discussion
Cisplatin is widely used in the treatment of bone
sarcomas, but does produce well-recognised neuro-
toxicity which can limit its use.
15± 17 Factors
in¯ uencing the degree of neurotoxicity from cis-
platin include total cumulative dose
15,18,19 the dose
of each individual injection, the schedule of drug
delivery
18,20± 22 renal function, and coincident or pre-
vious neurological damage from other condi-
tions.
23,24 Symptoms of peripheral parasthesiae
characteristically can occur after cumulative doses of
Fig. 1. Total dose of cisplatin (mg/m
2) received versus sum VPT
(vibration perception threshold) in 29 patients who received
cisplatin (r 5 0.607, p , 0.001).102 H. M. Earl et al.
Table 5. Neurophysiological evidence of sensory axonal neuropathy
No neuropathy Neuropathy
(mean 6 SD) (mean 6 SD) p(2-tail)
Age (years) 20.4 6 5 21.9 6 5.0 0.42
Height (cm) 168.2 6 12 172.0 6 8.3 0.36
TFI (weeks) 65.6 6 53.4 58.8 6 46.2 0.77
Cisplatin (mg m
2 2) 342.2 6 129 472.1 6 83.3 , 0.01*
Vincristine (mg) 19.2 6 8.7 10.7 6 1.2 0.13
Reflex score 7.8 6 2.5 4.0 6 3.4 , 0.005*
TFI, treatment-free interval in weeks.
*Statistically signi® cant result.
Fig. 2. Re¯ ex score versus sum VPT (vibration perception
threshold) in all 36 patients studied (r5 2 0.548, p , 0.001).
are relatively poorly protected by the blood barrier
and, as such, seem to be the most vulnerable neural
structures to the effects of neurotoxins.
30,31 Marked
degeneration and gliosis of the dorsal columns with
signi® cant axonal loss of the dorsal roots were
reported in a 3-year-old girl who had received
960 mg/m
2 of cisplatin.
32 The dorsal column in-
volvement is thought to be responsible for the oc-
casional case of Lhermitte’s sign reported in
association with the neuropathy.
33,34 There is still
some uncertainty whether the major cisplatin-
induced damage to the human sensory peripheral
nerves is at the level of the cell body, the axon, or
both. Although cisplatin toxicity is known to involve
predominantly large-diameter sensory ® bres, an
autonomic neuropathy has been described
14,35
occurring in patients receiving a combination of
cisplatin, vinblastine and bleomycin, and this has
been postulated to be a `dying back’ small-® bre
neuropathy. A motor component to the neuropathy
has been reported to occur in some patients receiv-
ing high doses of cisplatin.
36
This report adds to the experience of cisplatin
neuropathy in young people, and provides a com-
parison with an age-matched control population.
We have found evidence of a persisting sensory
axonal neuropathy in this group of young people
who received cisplatin as part of adjuvant chemo-
therapy treatment for bone and soft tissue sarcomas.
Ten of 29 patients (33%) who received cisplatin had
evidence of a sensory axonal neuropathy at a median
of 8 months after the completion of chemotherapy.
This is manifest by a reduction in the amplitude of
the sensory action potentials in sural and medial
300 mg/m
2 or greater, and at doses greater than
600 mg/m
2 severe disabling sensory ataxia and mo-
tor problems may be seen. Increases in VPT are
often the earliest manifestation of peripheral neu-
ropathy
25 usually preceding symptoms and signs by
6± 8 weeks.
26 They are found to be signi® cantly
elevated in patients who have received doses of
cisplatin . 300 mg/m
2.
27 This is followed by a re-
duction in amplitude
4 or absence
28 of sensory nerve
action potentials, consistent with a sensory axonal
neuropathy or ganglioneuropathy. It appears that
the neuropathy is due to a toxic effect on the dorsal
root ganglia, where tissue platinum levels have been
found to be the highest.
18,29 These sensory ganglia
Table 6. Correlations of neurophysiological parameters with re¯ ex score (n 5 36)
Linear Rank
Pearson’s r Kendall’s t p value
Medial plantar SNAP 0.52 0.37 , 0.005*
Medial plantar SCV 0.66 0.33 , 0.05*
Sural SNAP 0.50 0.39 , 0.05*
RVPT 2 0.53 2 0.36 , 0.005*
LVPT 2 0.52 2 0.34 , 0.01*
VPT SUM 2 0.55 2 0.38 , 0.05*
RVPT/AGE 2 0.60 2 0.37 , 0.005*
*Statistically signi® cant result.Long-term neurotoxicity of chemotherapy in adolescents 103
plantar nerves, and an increase in the VPT. Interest-
ingly the only clinical indication of neurological
damage was transient Lhermitte’s sign in one pa-
tient which persisted for only 2 months during
chemotherapy. No patients had parasthesiae, or
symptomatic sensory loss during chemotherapy or
as an immediate or late effect. Despite this nearly
one-third of patients were demonstrated to have a
sensory axonal neuropathy on NCS. The only clini-
cally detected abnormality was a reduction in re¯ ex
score, which was seen to a signi® cant extent in
16/36 (44%) of patients. The re¯ ex score correlated
with neurophysiological measurements, showing
signi® cant correlations with VPT, amplitude of
SNAP and SCV. Audiometric abnormalities were
demonstrated in 5/28 patients but these changes
were minor, and no patient had tinnitus or symp-
tomatic hearing loss. Minor abnormalities of auto-
nomic function were demonstrated in 4/22 patients,
and whether these patients are at signi® cant risk
from cardiorespiratory arrest, which has been re-
ported in patients with diabetes and autonomic dys-
function,
37 is uncertain, but seems unlikely.
Of some interest is the ® nding of signi® cant pro-
longation of f-wave latencies in the patient group as
a whole, which persisted after controlling for height,
and the relative slowing in motor conduction in the
posterior tibial nerve. As there is no sensory compo-
nent to the f-wave latency measurement, this sug-
gests that subtle motor involvement is detectable,
even in mild asymptomatic cases such as those
reported here. This could be a result of either a mild
diffuse disorder of myelination causing a slight slow-
ing of conduction velocity, or it could be the result
of mild axonal loss in which the large fastest con-
ducting ® bres are lost ® rst, resulting in a change in
the minimum f-wave latency, but not suf® cient to
cause a noticeable decrease in the CMAP ampli-
tude. The degree of axonal loss could be assessed by
further EMG studies of such a group of patients.
The VPT emerged in this study as the most
valuable single neurophysiological test in the assess-
ment of cisplatin-induced neuropathy in our pa-
tients. Measurement of VPT using the
Biothesiometer is a simple technique which does not
require the experienced training necessary for the
carrying out of other more sophisticated nerve con-
duction studies. The Biothesiometer is cheap, and
easily portable, and the test itself takes less than a
minute to perform and is entirely painless for the
patient. It is a quantitative measure which
signi® cantly correlated with cumulative cisplatin
dose, and could also be of use particularly in follow-
ing recovery after completion of chemotherapy. In
further research into cisplatin peripheral neuropa-
thy, VPT measurement using a Biothesiometer
could be recommended. This will be particularly
useful for long-term follow-up of younger patients.
Developments in this area of clinical cancer research
are likely to include the development of neuropro-
tectors, and the ease and acceptability of VPT
measurement with the Biothesiometer would make
this an obvious choice for collection of repeated
measurements within the context of randomised
clinical trials.
Reports concerning the progress of the neuropa-
thy are anecdotal. Improvement of the neuropathy
over time has been reported by some authors but
not by others.
25 It seems that some improvement
may occur after cessation of therapy, but de® cits do
remain affecting vibratory perception and proprio-
ception, which are considered largely irreversible
38
and which may progress.
39± 41 In our study there was
no correlation between the time from chemotherapy
and any of the clinical or neurophysiological
parameters, and this would suggest that there is not
signi® cant recovery, through time, of the sub-
clinical peripheral neuropathy documented in these
young people.
Cisplatin is used in combination with other cyto-
toxics in a number of chemo-curable malignancies
which affect young people, including bone sarcomas
and germ cell tumours. There has been recent con-
cern that its substitution by the less neurotoxic
analogue carboplatin in the treatment of metastatic
germ cell tumours has led to a signi® cant worsening
in outcome, because of a possible reduction in
ef® cacy.
42 It is likely that, for the foreseeable future,
cisplatin will remain an important component of
combination chemotherapy in a number of malig-
nancies in adolescents and young adults. Our study
adds further to the evidence of substantial neurotox-
icity of cisplatin in this group, in comparison with
age-matched controls, and lends important evidence
to arguments for the development of effective neu-
roprotectors.
21,43 The precise molecular mechanisms
of the neurological damage produced by cisplatin
are unknown. Possibilities include the reaction of
cisplatin with DNA in the dorsal root ganglia to
reduce the production of nerve growth factor, or
other neurotrophic proteins responsible for the
maintenance of an intact peripheral nervous system.
Other possibilities include the reaction of cisplatin
with neurotransport proteins. Whatever the mecha-
nisms of toxicity, the development of neuroprotec-
tors will be increasingly important. Several agents
have already been developed and used in this role.
44
These include WR 2721, a thiol derivative, which
has been used with the aim of reducing haematolog-
ical, renal and neurotoxicity.
39 Org 2766, a four-
amino acid derivative of ACTH
45 has been used
successfully in the prevention and amelioration of
neurotoxicity in patients with ovarian cancer.
46 Ex-
citing developments have recently been reported,
with the newly recognised nerve growth factors in
the regeneration of the peripheral nervous system
47
and the prevention of experimental cisplatin neu-
ropathy.
48 Insulin-like growth factor-I (IGF-I)
49 has
also been found to be a potent neurotrophic agent in
in vivo testing in an experimental rat model and is104 H. M. Earl et al.
entering Phase 2 testing in degenerative neurological
diseases. However IGF-I’s role as an active growth
factor in many tumours has delayed its testing in
cancer patients until the results of further in vitro
and in vivo tests are available.
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